JP MORGAN/CALL/MODERNA/155/0.1/21.06.24 | Real-time Bid/Ask 11:03:28 2024-06-17 EDT | ||
| 0.01 EUR / 0.05 EUR | +11.11% |
|
| Current month | -90.69% | ||
| 1 month | -79.23% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-17 | 0.007 | -74.07% |
| 24-06-14 | 0.027 | -66.25% |
| 24-06-13 | 0.08 | -46.67% |
| 24-06-12 | 0.15 | -28.57% |
| 24-06-11 | 0.21 | -8.70% |
Delayed Quote Börse Stuttgart
Last update June 17, 2024 at 10:36 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | J.P. Morgan |
| WKN | JS8JSR |
| ISIN | DE000JS8JSR8 |
| Date issued | 2023-02-27 |
| Strike | 155 $ |
| Maturity | 2024-06-21 (4 Days) |
| Parity | 10 : 1 |
| Emission price | 3.38 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.18 € |
|---|---|
| Lowest since issue | 0.007 € |
| Spread | 0.05 € |
| Spread % | 87.72% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Warrants
- Warrant
